|
1
|
Wu L, Chang W, Zhao J, Yu Y, Tan X, Su T,
Zhao L, Huang S, Liu S and Cao G: Development of autoantibody
signatures as novel diagnostic biomarkers of non-small cell lung
cancer. Clin Cancer Res. 16:3760–3768. 2010.PubMed/NCBI
|
|
2
|
Rigas JR and Kelly K: Current treatment
paradigms for locally advanced non-small cell lung cancer. J Thorac
Oncol. 2:(Suppl 2). S77–S85. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Choy H, Pyo H, Kim JS and MacRae R: Role
of taxanes in the combined modality treatment of patients with
locally advanced non-small cell lung cancer. Expert Opin
Pharmacother. 2:963–974. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wakelee H, Ramalingam S and Belani CP:
Docetaxel in advanced non-small cell lung cancer. Expert Rev
Anticancer Ther. 5:13–24. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stinchcombe TE: Recent advances in the
treatment of non-small cell and small cell lung cancer. F1000Prime
Rep. 6:1172014. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Garon EB, Ciuleanu TE, Arrieta O, Prabhash
K, Syrigos KN, Goksel T, Park K, Gorbunova V, Kowalyszyn RD, Pikiel
J, et al: Ramucirumab plus docetaxel versus placebo plus docetaxel
for second-line treatment of stage IV non-small-cell lung cancer
after disease progression on platinum-based therapy (REVEL): A
multicentre, double-blind, randomised phase 3 trial. Lancet.
384:665–673. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yoh K, Hosomi Y, Kasahara K, Yamada K,
Takahashi T, Yamamoto N, Nishio M, Ohe Y, Koue T, Nakamura T, et
al: A randomized, double-blind, phase II study of ramucirumab plus
docetaxel vs. placebo plus docetaxel in Japanese patients with
stage IV non-small cell lung cancer after disease progression on
platinum-based therapy. Lung Cancer. 99:186–193. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Lage H: An overview of cancer multidrug
resistance: A still unsolved problem. Cell Mol Life Sci.
65:3145–3167. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Myer MS, Joone G, Chasen MR and van
Rensburg CE: The chemosensitizing potential of GF120918 is
independent of the magnitude of P-glycoprotein-mediated resistance
to conventional chemotherapeutic agents in a small cell lung cancer
line. Oncol Rep. 6:217–218. 1999.PubMed/NCBI
|
|
10
|
Galletti E, Magnani M, Renzulli ML and
Botta M: Paclitaxel and docetaxel resistance: Molecular mechanisms
and development of new generation taxanes. ChemMedChem. 2:920–942.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Luqmani YA: Mechanisms of drug resistance
in cancer chemotherapy. Med Princ Pract. 14:(Suppl 1). S35–S48.
2005. View Article : Google Scholar
|
|
13
|
Gottesman MM and Ambudkar SV: Overview:
ABC transporters and human disease. J Bioenerg Biomembr.
33:453–458. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sarkadi B, Homolya L, Szakács G and Váradi
A: Human multidrug resistance ABCB and ABCG transporters:
Participation in a chemoimmunity defense system. Physiol Rev.
86:1179–1236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Higgins CF: Multiple molecular mechanisms
for multidrug resistance transporters. Nature. 446:749–757. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sharom FJ: ABC multidrug transporters:
Structure, function and role in chemoresistance. Pharmacogenomics.
9:105–127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Y, Yuan H, Yang K, Xu W, Tang W and Li
X: The structure and functions of P-glycoprotein. Curr Med Chem.
17:786–800. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Szakács G, Váradi A, Ozvegy-Laczka C and
Sarkadi B: The role of ABC transporters in drug absorption,
distribution, metabolism, excretion and toxicity (ADME-Tox). Drug
Discov Today. 13:379–393. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Palmeira A, Sousa E, Vasconcelos MH and
Pinto MM: Three decades of P-gp inhibitors: Skimming through
several generations and scaffolds. Curr Med Chem. 19:1946–2025.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: Evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hubensack M, Müller C, Höcherl P, Fellner
S, Spruss T, Bernhardt G and Buschauer A: Effect of the ABCB1
modulators elacridar and tariquidar on the distribution of
paclitaxel in nude mice. J Cancer Res Clin Oncol. 134:597–607.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.PubMed/NCBI
|
|
23
|
Min C, Eddy SF, Sherr DH and Sonenshein
GE: NF-kappaB and epithelial to mesenchymal transition of cancer. J
Cell Biochem. 104:733–744. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sabbah M, Emami S, Redeuilh G, Julien S,
Prévost G, Zimber A, Ouelaa R, Bracke M, De Wever O and Gespach C:
Molecular signature and therapeutic perspective of the
epithelial-to-mesenchymal transitions in epithelial cancers. Drug
Resist Updat. 11:123–151. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ren J, Chen Y, Song H, Chen L and Wang R:
Inhibition of ZEB1 reverses EMT and chemoresistance in
docetaxel-resistant human lung adenocarcinoma cell line. J Cell
Biochem. 114:1395–1403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu C and Alman BA: Side population cells
in human cancers. Cancer Lett. 268:1–9. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sugano T, Seike M, Noro R, Soeno C, Chiba
M, Zou F, Nakamichi S, Nishijima N, Matsumoto M, Miyanaga A, et al:
Inhibition of ABCB1 overcomes cancer stem cell-like properties and
acquired resistance to MET inhibitors in non-small cell lung
cancer. Mol Cancer Ther. 14:2433–2440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
O'Flaherty JD, Barr M, Fennell D, Richard
D, Reynolds J, O'Leary J and O'Byrne K: The cancer stem-cell
hypothesis: Its emerging role in lung cancer biology and its
relevance for future therapy. J Thorac Oncol. 7:1880–1890. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Reya T, Morrison SJ, Clarke MF and
Weissman IL: Stem cells, cancer, and cancer stem cells. Nature.
414:105–111. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Berns A: Stem cells for lung cancer? Cell.
121:811–813. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiang F, Qiu Q, Khanna A, Todd NW, Deepak
J, Xing L, Wang H, Liu Z, Su Y, Stass SA and Katz RL: Aldehyde
dehydrogenase 1 is a tumor stem cell-associated marker in lung
cancer. Mol Cancer Res. 7:330–338. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shien K, Toyooka S, Yamamoto H, Soh J,
Jida M, Thu KL, Hashida S, Maki Y, Ichihara E, Asano H, et al:
Acquired resistance to EGFR inhibitors is associated with a
manifestation of stem cell-like properties in cancer cells. Cancer
Res. 73:3051–3061. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang YJ, Zhang YK, Kathawala RJ and Chen
ZS: Repositioning of tyrosine kinase inhibitors as antagonists of
ATP-binding cassette transporters in anticancer drug resistance.
Cancers (Basel). 6:1925–1952. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Scheel C and Weinberg RA: Phenotypic
plasticity and epithelial-mesenchymal transitions in cancer and
normal stem cells? Int J Cancer. 129:2310–2314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hennessy BT, Gonzalez-Angulo AM,
Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J,
Sahin A, Agarwal R, Joy C, et al: Characterization of a naturally
occurring breast cancer subset enriched in
epithelial-to-mesenchymal transition and stem cell characteristics.
Cancer Res. 69:4116–4124. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Gal A, Sjöblom T, Fedorova L, Imreh S,
Beug H and Moustakas A: Sustained TGF beta exposure suppresses Smad
and non-Smad signalling in mammary epithelial cells, leading to EMT
and inhibition of growth arrest and apoptosis. Oncogene.
27:1218–1230. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan
A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Dean M: ABC transporters, drug resistance,
and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Resetkova E, Reis-Filho JS, Jain RK, Mehta
R, Thorat MA, Nakshatri H and Badve S: Prognostic impact of ALDH1
in breast cancer: A story of stem cells and tumor microenvironment.
Breast Cancer Res Treat. 123:97–108. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Holohan C, Van Schaeybroeck S, Longley DB
and Johnston PG: Cancer drug resistance: An evolving paradigm. Nat
Rev Cancer. 13:714–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mizuuchi H, Suda K, Sato K, Tomida S,
Fujita Y, Kobayashi Y, Maehara Y, Sekido Y, Nishio K and Mitsudomi
T: Collateral chemoresistance to anti-microtubule agents in a lung
cancer cell line with acquired resistance to erlotinib. PLoS One.
10:e01239012015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Goldman B: Multidrug resistance: Can new
drugs help chemotherapy score against cancer? J Natl Cancer Inst.
95:255–257. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mayur YC, Peters GJ, Prasad VV, Lemo C and
Sathish NK: Design of new drug molecules to be used in reversing
multidrug resistance in cancer cells. Curr Cancer Drug Targets.
9:298–306. 2009. View Article : Google Scholar : PubMed/NCBI
|
